Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai MicroPort MedBot (Group) Co., Ltd.
上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform its shareholders and potential investors that the Group continue to deepen the domestic market and accelerate the expansion of overseas market layout, with a firm determination in promoting the business-focused and global expansion strategies amid the challenging global macroeconomic development and fiercer market competition within the industry in the first half of 2024.

The Board expects that the revenue of the Company for the six months ended 30 June 2024 (the "**Period**") will achieve a significant year-on-year growth of approximately 103% to 108% as compared to that for the six months ended 30 June 2023, which is mainly attributable to following reasons:

1. Toumai Laparoscopic Surgical Robot (the "**Toumai**"), the core product, has maintained its strong sales momentum in domestic market, and ranked first in the market share of domestic laparoscopic surgical robots during the Period; at the same time, Toumai has successfully completed first overseas commercial installation and achieved revenue breakthroughs. Its overseas market expansion process has been further accelerated with the cumulative overseas orders exceeding ten units especially after being awarded the certification from EU CE in May 2024;

2. The SkyWalker orthopedic surgical robot fully leveraged its synergies with MicroPort Group during the Period, gradually expanding its global presence to over 20 countries across five continents. It achieved sales revenues in the United States, Europe, Australia, and other regions, achieving a twofold increase in sales compared to the same period last year;

3. The launch of new products contributed to an increase in revenue. Among the new products, the in-hospital promotion of the R-ONE vascular interventional robot that approved in December 2023 accelerated. The product also recorded its first installation and generated revenue during the Period.

As at the date of this announcement, the Company is still in the process of preparing and completing the interim results of the Company for the six months ended 30 June 2024. The data contained in this announcement is only based on a preliminary assessment of the consolidated management accounts and relevant data available to the Board as of the date of the announcement, and may be subject to adjustments. The interim results announcement of the Company for the six months ended 30 June 2024 will be published on or before 31 August 2024. Shareholders of the Company and potential investors are advised to read carefully the interim results announcement upon publication.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 4 July 2024

As at the date of this announcement, the executive director is Dr. He Chao, the non-executive directors are Mr. Sun Hongbin, Mr. Chen Xinxing and Mr. Chen Chen, and the independent non-executive directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Mui Wing Hong.